Immune-mediated disease units: A step forward for patients with inflammatory bowel disease
Immune-mediated inflammatory diseases (IMIDs) are a group of chronic and, up to date, incurable disorders affecting 5-7% of the Western population that share common pathophysiologic mechanisms. IMIDs may generate long-term disability as well as a significant reduction quality of life, causing a high socio-sanitary impact. Approximately, 20% of patients diagnosed with IMID suffer from at least another coexisting IMID and other comorbidities are also frequent, which has a significant impact on their therapeutic management. Moreover, the transversality and the associated complexity of caring for these patients make its multidisciplinary management necessary and represent a challenge for the traditional structure of health-care services. In this context, IMID multidisciplinary units emerge as a new collaborative care model that could provide an optimal framework for sharing clinical decisions between different specialists involved in the care of these patients. Some of the main goals of this multidisciplinary model should be the early diagnosis of concomitant IMIDs, the optimization of the treatment and the improvement the quality of care. For this purpose, shared decision about the most appropriate care plan and a multidisciplinary consultation must be warranted. In addition, IMIDs units should offer supporting programs such as those rely on the prevention of potentially avoidable transmissible diseases, neoplasms related to immunosuppression, and cardiovascular disease; resources of psychological support; and programs of transition from pediatric to adult healthcare..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Journal of IMIDs - 2(2022), 2 |
| Sprache: |
Englisch ; Spanisch |
|---|
| Beteiligte Personen: |
Esther Chamorro-de-Vega [VerfasserIn] |
|---|
| Links: |
doaj.org [kostenfrei] |
|---|
| Themen: |
Dermatology |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ020731949 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ020731949 | ||
| 003 | DE-627 | ||
| 005 | 20230307041457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ020731949 | ||
| 035 | |a (DE-599)DOAJ12a915c7f97f4d8e829d14017afc26bd | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa | ||
| 050 | 0 | |a RL1-803 | |
| 050 | 0 | |a RC799-869 | |
| 100 | 0 | |a Esther Chamorro-de-Vega |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune-mediated disease units: A step forward for patients with inflammatory bowel disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Immune-mediated inflammatory diseases (IMIDs) are a group of chronic and, up to date, incurable disorders affecting 5-7% of the Western population that share common pathophysiologic mechanisms. IMIDs may generate long-term disability as well as a significant reduction quality of life, causing a high socio-sanitary impact. Approximately, 20% of patients diagnosed with IMID suffer from at least another coexisting IMID and other comorbidities are also frequent, which has a significant impact on their therapeutic management. Moreover, the transversality and the associated complexity of caring for these patients make its multidisciplinary management necessary and represent a challenge for the traditional structure of health-care services. In this context, IMID multidisciplinary units emerge as a new collaborative care model that could provide an optimal framework for sharing clinical decisions between different specialists involved in the care of these patients. Some of the main goals of this multidisciplinary model should be the early diagnosis of concomitant IMIDs, the optimization of the treatment and the improvement the quality of care. For this purpose, shared decision about the most appropriate care plan and a multidisciplinary consultation must be warranted. In addition, IMIDs units should offer supporting programs such as those rely on the prevention of potentially avoidable transmissible diseases, neoplasms related to immunosuppression, and cardiovascular disease; resources of psychological support; and programs of transition from pediatric to adult healthcare. | ||
| 650 | 4 | |a Immune-mediated inflammatory diseases. Patient care team. Comprehensive health care. Interdisciplinary communication. | |
| 653 | 0 | |a Dermatology | |
| 653 | 0 | |a Diseases of the digestive system. Gastroenterology | |
| 700 | 0 | |a Luis Menchén |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of IMIDs |d Publicaciones Permanyer, 2022 |g 2(2022), 2 |w (DE-627)DOAJ078620899 |x 2696824X |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2022 |g number:2 |
| 856 | 4 | 0 | |u https://doaj.org/article/12a915c7f97f4d8e829d14017afc26bd |z kostenfrei |
| 856 | 4 | 0 | |u https://www.journalofimids.com/frame_esp.php?id=18 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2696-824X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2022 |e 2 | ||